The Food and Drug Administration clearance and CE mark position Abbott to sell its Amplatzer Piccolo Delivery System in the U ...

The US Food and Drug Administration (FDA) has approved the Amplatzer Piccolo Occluder (Abbott), the first medical device to treat patent ductus arteriosus (PDA) in premature babies weighing as little ...

A PDA requiring treatment is present in approximately 20% of premature infants 1 ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug ...

Mumbai: Abbott on Tuesday announced that it has launched its Amplatzer Piccolo Occluder in India, the world's first medical device that can be implanted in the tiniest babies using a minimally ...

Chicago-based Abbott Laboratories received an FDA approval for the Amplatzer Piccolo Occluder to treat patent ductus arteriosus (PDA), a condition in which a newborn has a persistent opening in the ...

Abbott’s range of entries to Fast Company’s 2o20 World Changing Ideas Awards made it our selection for World Changing Company of the Year. While the company is currently a major player in helping ramp ...

Abbott ABT recently has initiated a U.S. pivotal clinical study to evaluate the safety and effectiveness of a modified version of its AMPLATZER device. This device is designed to correct a common ...

ABBOTT PARK, Ill., Dec. 18, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer Piccolo™ Delivery ...

First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise ...

First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery ...